Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18618894 | PLACENTAL MESENCHYMAL STEM CELLS, METHODS OF PRODUCTION, AND PLACENTAL MESENCHYMAL STEM CELL BASED THERAPEUTICS | March 2024 | February 2026 | Abandon | 23 | 1 | 1 | No | No |
| 18221026 | SYSTEMS AND METHODS FOR PRODUCING INJECTABLE ENHANCED STEM CELL EXOSOMES, IMPROVED EXOSOMES AND METHODS OF USE | July 2023 | March 2025 | Allow | 20 | 4 | 1 | Yes | No |
| 18341701 | MESENCHYMAL STEM CELLS FOR TREATMENT OF SKIN DISORDERS AND SKIN PROBLEMS | June 2023 | August 2025 | Abandon | 26 | 3 | 0 | No | No |
| 18100437 | METHODS OF PREPARING A PRIMARY CELL SAMPLE | January 2023 | September 2024 | Allow | 20 | 1 | 0 | No | No |
| 18003392 | CRANIAL NEUROPATHY THERAPEUTIC AGENT CONTAINING CULTURE SUPERNATANT FOR UMBILICAL CORD BLOOD MONOCYTIC CELLS | December 2022 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18056371 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | November 2022 | August 2025 | Abandon | 33 | 3 | 1 | No | No |
| 17912246 | CORD BLOOD PLASMA-DERIVED EXOSOME OR MIMETIC THEREOF AND PHARMACEUTICAL USE THEREOF | September 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17841089 | METHODS FOR IMPROVING MYELOID BRIDGING IN CORD BLOOD TRANSPLANT RECIPIENTS | June 2022 | April 2025 | Abandon | 34 | 2 | 0 | No | No |
| 17838068 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE | June 2022 | December 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17696625 | PROCESSES AND AGENTS FOR GLAUCOMA | March 2022 | August 2025 | Abandon | 41 | 5 | 1 | No | No |
| 17685180 | IMMUNOSUPPRESSIVE THERAPIES FOR USE WITH CARDIOMYOCYTE CELL THERAPIES, AND ASSOCIATED METHODS AND COMPOSITIONS | March 2022 | May 2025 | Abandon | 39 | 4 | 0 | No | No |
| 17585094 | METHODS OF PREVENTATIVE THERAPY FOR POST-TRAUMATIC OSTEOARTHRITIS | January 2022 | March 2026 | Abandon | 49 | 4 | 1 | No | No |
| 17569282 | ANTI-AGING COMPOSITIONS AND USES THEREOF | January 2022 | November 2025 | Allow | 47 | 4 | 1 | Yes | No |
| 17501759 | Engineered Extracellular Vesicle Delivery Systems and Uses Thereof | October 2021 | June 2025 | Abandon | 44 | 3 | 1 | No | No |
| 17417619 | GENE THERAPY CONSTRUCTS FOR TREATING WILSON DISEASE | June 2021 | April 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17416311 | ADENO-ASSOCIATED VIRUSES AND THEIR USES FOR INNER EAR THERAPY | June 2021 | April 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17342158 | Composition and Use of Interleukin Stimulated Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Rheumatoid Arthritis | June 2021 | November 2024 | Abandon | 41 | 4 | 1 | Yes | No |
| 17290418 | DNA VECTOR FOR TARGETED GENE THERAPY | April 2021 | November 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17287431 | SYNP78 (PROA27), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS | April 2021 | March 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17284536 | CODON-OPTIMIZED TRANSGENE FOR THE TREATMENT OF PROGRESSIVE FAMILIAR INTRAHEPATIC CHOLESTASIS TYPE 3 (PFIC3) | April 2021 | September 2025 | Abandon | 53 | 2 | 0 | Yes | No |
| 17228276 | USE OF IMMORTALIZED PLACENTAL STEM CELLS IPSC/EXTRACELLULAR VESICLES TO ENHANCE THERAPEUTIC RECOVERY FROM TISSUE DAMAGE AND ISCHEMIA-REPERFUSION INJURY AND DELAYED ORGAN FUNCTION | April 2021 | October 2025 | Abandon | 55 | 4 | 1 | No | No |
| 17200693 | INJECTION SOLUTION FOR RNA | March 2021 | October 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17143866 | ANGIOGENESIS USING STIMULATED PLACENTAL STEM CELLS | January 2021 | September 2025 | Abandon | 56 | 3 | 1 | No | No |
| 17114784 | COMPOSITIONS AND METHODS FOR TREATING STROKE | December 2020 | December 2025 | Abandon | 60 | 4 | 1 | No | Yes |
| 17077683 | ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES AND DISORDERS | October 2020 | February 2026 | Abandon | 60 | 4 | 1 | No | No |
| 17046243 | ENGINEERED CYTOLYTIC IMMUNECELL | October 2020 | June 2025 | Abandon | 56 | 3 | 1 | No | No |
| 16647565 | THERAPEUTIC USES OF FLAP OF GENETICALLY MODIFIED CELLS | March 2020 | September 2025 | Abandon | 60 | 5 | 0 | No | No |
| 16645840 | ENRICHMENT OF NKX6.1 AND C-PEPTIDE CO-EXPRESSING CELLS DERIVED IN VITRO FROM STEM CELLS | March 2020 | December 2024 | Abandon | 57 | 3 | 1 | No | No |
| 16636249 | PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS | February 2020 | December 2024 | Abandon | 58 | 4 | 0 | No | No |
| 16630872 | CELL CULTURING MATERIALS | January 2020 | October 2024 | Allow | 57 | 4 | 1 | No | Yes |
| 16604680 | PLATELET VESICLE-ENGINEERED CELLS FOR TARGETED TISSUE REPAIR | October 2019 | October 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16566675 | COMPOSITIONS AND METHODS FOR MICROGLIA REPLACEMENT THERAPY | September 2019 | July 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16469608 | MODULATION OF ISCHEMIC CELL BIOENERGETICS | June 2019 | January 2026 | Abandon | 60 | 5 | 1 | Yes | No |
| 16331426 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING IMMUNE DISEASE OR INFLAMMATORY DISEASE INCLUDING INFLAMMATORY STIMULATED MESENCHYMAL STEM CELL | March 2019 | February 2026 | Abandon | 60 | 7 | 1 | No | No |
| 16096967 | Derivation and Self-Renewal of Multipotent Cells and Uses Thereof | October 2018 | October 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16113813 | METHODS AND COMPOSITIONS FOR THE PRESERVATION OF TISSUE | August 2018 | October 2024 | Abandon | 60 | 5 | 0 | Yes | Yes |
| 16072345 | IMMUNE CELL SELECTION, EXPANSION, AND USE | July 2018 | January 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16043520 | ACELLULAR REGENERATIVE PRODUCTS AND METHODS OF THEIR MANUFACTURE | July 2018 | December 2023 | Abandon | 60 | 5 | 0 | No | Yes |
| 15420901 | TISSUE-ENGINEERED CONSTRUCTS | January 2017 | December 2024 | Abandon | 60 | 8 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CONNORS, ALEXANDRA F.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CONNORS, ALEXANDRA F works in Art Unit 1634 and has examined 26 patent applications in our dataset. With an allowance rate of 15.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 58 months.
Examiner CONNORS, ALEXANDRA F's allowance rate of 15.4% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CONNORS, ALEXANDRA F receive 3.73 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CONNORS, ALEXANDRA F is 58 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +27.5% benefit to allowance rate for applications examined by CONNORS, ALEXANDRA F. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 0.0% of applications are subsequently allowed. This success rate is in the 0% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 14.3% of cases where such amendments are filed. This entry rate is in the 15% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 33.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 125.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.